TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LEVOLEUCOVORIN CALCIUM

LEVOLEUCOVORIN CALCIUM
Oncology Approved 2015-03-09
12
Indications
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2015-03-09
Routes
INTRAVENOUS
Dosage Forms
SOLUTION, POWDER

LEVOLEUCOVORIN CALCIUM Approval History

Loading approval history...

What LEVOLEUCOVORIN CALCIUM Treats

4 indications

LEVOLEUCOVORIN CALCIUM is approved for 4 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Osteosarcoma
  • Folic Acid Antagonist Overdose
  • Methotrexate Elimination Impairment
  • Colorectal Cancer
Source: FDA Label
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEVOLEUCOVORIN CALCIUM FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite he...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.